Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 109-112

  Dişel, Umut ^a   Öztuzcu, Serdar ^b   Beşen, Ali Ayberk ^a   Karadeniz, Cemile ^a   Köse, Fatih ^a   Sümbül, Ahmet Taner ^a   Sezer, Ahmet ^a   Nursal, Gül Nihal ^a   Abali, Hüseyin ^a   Özyilkan, Özgür ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

C KIT; C KIT mutation; Sorafenib; Thymic carcinoma; TKI inhibitors

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; SORAFENIB; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DELETION MUTANT; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; ERYTHEMA; EXON; FATIGUE; FEMALE; HUMAN; MEDIASTINOSCOPY; ONCOGENE C KIT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN MANIFESTATION; THYMUS CANCER; THYMUS CARCINOMA; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; EXONS; FEMALE; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; PYRIDINES; SEQUENCE DELETION; THYMUS NEOPLASMS;

EID: 78650189002     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.09.011     Document Type: Article

References (13)

1. Koizumi T., Takabayashi Y., Yamagishi S., Tsushima K., Takamizawa A., Tsukadaira A., et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002, 25(June (3)):266-268.
2. Ito J., Sekiya M., Miura K., Yoshimi K., Suzuki T., Seyama K., et al. Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone. Intern Med 2009, 48(12):1061-1064.
3. Pan C.C., Chen P.C., Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004, 202(March (3)):375-381.
4. Tsuchida M., Umezu H., Hashimoto T., Shinohara H., Koike T., Hosaka Y., et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 2008, 62(December (3)):321-325.
5. Yoh K., Nishiwaki Y., Ishii G., Goto K., Kubota K., Ohmatsu H., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62(December (3)):316-320.
6. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999, 59(September (17)):4297-4300.
7. Hasskarl J. Sorafenib. Recent results. Cancer Res 2010, 184:61-70.
8. Ströbel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004, 350(June (25)):2625-2626.
9. Bisagni G., Rossi G., Cavazza A., Sartori G., Gardini G., Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009, 4(June (6)):773-775.
10. Tomita M., Matsuzaki Y., Edagawa M., Maeda M., Shimizu T., Hara M., et al. Correlation between tumor angiogenesis and invasiveness in thymic epithel tumors. J Thorac Cardiovasc Surg 2002, 124(September (3)):493-498.
11. Li X.F., Chen Q., Huang W.X., Ye Y.B. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009, 26(2):157-160.
12. Lynch T.J., Bell D.W., Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
13. Chou T.Y., Chiu C.H., Li L.H., Hsiao C.Y., Tzen C.Y., Chang K.T., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:3750-3757.